In our January issue of Pharmaceutical Executive FEATURES
Cover Story Pharm Exec’s 2018 Industry Forecast Pharm Exec Editors
In our annual temperature check on the life sciences sector and its outlook for the months ahead, we explore eight trends that will shape the biopharma industry landscape in 2018.
Interview From Gleevec to CAR-T PharmaBoardroom
Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer—starting with Gleveec and continuing with last year’s approval of the first-ever CAR-T cell therapy—touching on the related broader issues such as pricing and value and new innovations in cancer science.
Technology New Year, Next Steps in Digital Transformation William King
Five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.
ALSO IN THIS ISSUE CAR-T Concerns for Future Success Lisa Henderson
The advent of immunocellular therapies marks a major milestone in medical innovation, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance …Read more